Shawn Leland - Feb 14, 2022 Form 4 Insider Report for Elevation Oncology, Inc. (ELEV)

Role
President, CEO, Director
Signature
/s/ Tammy Furlong, Attorney-in-Fact
Stock symbol
ELEV
Transactions as of
Feb 14, 2022
Transactions value $
$0
Form type
4
Date filed
2/16/2022, 07:08 PM
Previous filing
Jun 24, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELEV Employee Stock Option (Right to Buy) Award $0 +187K $0.00 187K Feb 14, 2022 Common Stock 187K $3.78 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests as to 25% of the total shares on February 10, 2023, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date and is subject to acceleration in the event of a change in control of the Issuer.